Skip to main content
All lobbying filings

ALSTON & BIRD LLP

Lobbying for TRAVERE THERAPEUTICS · Prescription pharmaceutical manufacturer of medications.

 Filing 2nd Quarter - Report
2nd Quarter (Apr 1 - June 30) 2026 · California · House · Senate · $70,000.00 income · posted Jul 20, 2026

Official filing document

 Bills named in this filing 3
 Lobbying activity 5
Health Issues

Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Support of reauthorization of priority review voucher program. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs.

Medicare/Medicaid

H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs, Medicare and Medicaid.

Pharmacy

Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs. Most-Favored Nation and International Reference Pricing proposals. PDUFA/regulatory review process.

Medical/Disease Research/Clinical Labs

The Newborn Screening Reauthorization Act, and improving funding of newborn screening implementation; Importance of patient voice in rare kidney disease.

Taxation/Internal Revenue Code

H.R.1414, Camerons Law, to restore the amount of the Orphan Drug Tax Credit.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem